A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease

Trial Profile

A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Sickle cell anaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Acronyms HOPE-KIDS 1
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 01 Nov 2017 According to a Global Blood Therapeutics media release, updated data will be presented at the 59th American Society of Hematology (ASH) Annual Meeting & Exposition.
    • 11 Oct 2017 According to a Global Blood Therapeutics media release, data were presented at the Academy for Sickle Cell and Thalassemia (ASCAT) 11th Annual Conference in London.
    • 07 Aug 2017 According to a Global Blood Therapeutics media release, dosing of Cohort 2 has been completed the third-quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top